Andere talen GSK plc

Aandelen

GSK

GB00BN7SWP63

Geschatte realtime Cboe Europe Andere beurzen 13:35:34 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.587 ^GBX	+0,22%		-3,44%	+9,43%

17/04	Met vallen en opstaan: waterstof
17/04	GSK plc kondigt nieuwe langetermijngegevens aan die aantonen dat Shingrix gedurende meer dan een decennium een hoge bescherming blijft bieden tegen gordelroos bij volwassenen van 50 jaar en ouder	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Studie: Brexit-Folgen verschärfen britische Arzneimittelknappheit	18/04
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	17/04
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	17/04
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	17/04
GSK : résultats cliniques positifs dans la gonorrhée	17/04
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	17/04
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	17/04
GSK : le virus contre le zona efficace pendant plus de 10 ans	17/04
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA \| GSK	17/04
GSK hails data on Shingles vaccine and gonorrhoea treatment	17/04
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	17/04
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	17/04
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	17/04
GSK : New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	17/04
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	17/04
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	16/04
No habia que invitarlo: El hidrógeno	16/04
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review	16/04
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA - Form 6-K	16/04
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate	16/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

GSK PLC : 2023 sterk geëindigd; middellange- tot langetermijnbegeleiding verhoogd

02 februari 2024 om 15:40 uur

Met vallen en opstaan: GSK

16 juni 2023 om 12:20 uur